Phase 2 N=275 A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Resistant Hypertension
Primary: Change From Baseline in Mean Seated Systolic BP (SBP) — -12.4; -17.3; -19.2; -9.8 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=78 A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
Cystic Fibrosis
Primary: Absolute Change From Baseline Through Day 29 in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.3; -2.2; 2.0; 4.5 percent predicted FEV1 (%)
Phase 2 N=54 Multiple Doses of AT-1501-A201 in Adults With ALS
Amyotrophic Lateral Sclerosis
Primary: Safety and Tolerability — 8; 8; 10; 16 participants
Phase 2 N=36 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Lymphoid Leukemia · Small Lymphocytic Lymphoma · Lymphoma, Non-Hodgkin
Primary: Time to Progression — 4.76 years
Phase 2 N=95 Thiamine as a Renal Protective Agent in Septic Shock
Sepsis · Kidney Injury · Thiamine Deficiency
Primary: Kidney Injury Biomarker — 2.24; 2.79 mg/dL — p=0.07
Phase 2 N=300 Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults
Pertussis · Whooping Cough
Primary: Number of Participants With Nasal Mucosal Seroconversion (Immunoglobulin A [IgA]) — 79; 89; 38; 42 Participants
Phase 2 N=46 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Phase 2 N=48 Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Primary: Percentage of Participants With None or Mild in GL Severity at Maximum Frown — 46 Participants
Phase 2 N=28 In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area
Surgical Skin Preparation · Surgical Procedure, Unspecified
Primary: Comparison of Log Change of Skin Flora Relative to Pre-treatment (Baseline) in Each of 3 Sampling Sites at a Defined Post-treatment Sampling Time. — -2.19; -1.85; -2.42…
Phase 2 N=132 A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain After Cataract Surgery
Primary: Number of Treatment Emergent Adverse Events — 4; 7; 3; 8 Participants
Phase 2 N=63 Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Lateral Canthal Lines
Primary: Percentage of Participants With None or Mild in LCL Severity at Maximum Smile — 9; 10; 8; 14 Participants
Phase 2 N=34 Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Phase 2 N=167 The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps — 0; 5; 2 eyes — p=0.495
Phase 2 N=24 Trial of Aspirin and Arginine Restriction in Colorectal Cancer
Colorectal Cancer
Primary: Rectal Tissue Putrescine Reduction — 17 Participants
Phase 2 N=78 Phase 2 Bunionectomy HTX-011 Administration Study
Postoperative Pain
Primary: Mean Area Under the Curve (AUC) of the NRS-A (Windowed Worst Observation Carried Forward) Pain Intensity Scores — 278.36; 288.23; 126.93 pain intensity score*hr